Chemomab Therapeutics Announced Publication Of Proteomic Analyses That Further Demonstrate The Unique Role Of The Soluble Protein CCL24 In Driving Pathologies Associated With The Rare Fibrotic Liver Disease Primary Sclerosing Cholangitis
Chemomab Therapeutics Announced Publication Of Proteomic Analyses That Further Demonstrate The Unique Role Of The Soluble Protein CCL24 In Driving Pathologies Associated With The Rare Fibrotic Liver Disease Primary Sclerosing Cholangitis
Chemomab Therapeutics 宣佈發表蛋白質組學分析，進一步證明了可溶性蛋白 CCL24 在驅動與罕見纖維化肝病原發性硬化性膽管炎相關的病理中的獨特作用
Chemomab Therapeutics Announced Publication Of Proteomic Analyses That Further Demonstrate The Unique Role Of The Soluble Protein CCL24 In Driving Pathologies Associated With The Rare Fibrotic Liver Disease Primary Sclerosing Cholangitis
Chemomab Therapeutics 宣佈發表蛋白質組學分析，進一步證明了可溶性蛋白 CCL24 在驅動與罕見纖維化肝病原發性硬化性膽管炎相關的病理中的獨特作用
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。